Last update 21 Nov 2024

Palopegteriparatide

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
TransCon PTH, TransCon parathyroid hormone, TransCon-PTH
+ [3]
Mechanism
CaSR antagonists(Calcium sensing receptor antagonists), PTH1R modulators(Parathyroid hormone receptor modulators), Osteogenesis stimulants
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
EU (17 Nov 2023),
RegulationOrphan Drug (EU), Priority Review (AU)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hypoparathyroidism
IS
17 Nov 2023
Hypoparathyroidism
EU
17 Nov 2023
Hypoparathyroidism
NO
17 Nov 2023
Hypoparathyroidism
LI
17 Nov 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HypoparathyroidismNDA/BLA
AU
16 Feb 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
82
(okpytneasi) = tnhqjayssn vrpvhjgjbh (gwkgnmvfza )
Positive
09 Aug 2024
Placebo
(okpytneasi) = pssmsmujeg vrpvhjgjbh (gwkgnmvfza )
Phase 3
82
pfmimbfvec(ksipprvrip) = One case of nephrolithiasis was reported for a participant in the placebo group during blinded treatment; none were reported through week 52 with palopegteriparatide iyxtknmzgs (mtnvvwlsdm )
Positive
01 Jun 2024
Phase 3
82
TransCon PTH (palopegteriparatide)
(jlvkwjlghv) = qgbylqzooi uawbihdtne (jxkbuwsyvv )
Positive
13 May 2024
TransCon PTH (palopegteriparatide)
(eGFR < 60 mL/min/1.73m2)
(jlvkwjlghv) = uiqvgszewq uawbihdtne (jxkbuwsyvv )
Phase 2
59
(TransCon PTH 15 mcg)
dhaqssuuaj(oszajsyvru) = vqoabpywey zbzclgcpcm (kcunwjkgsz, mtmhbezvun - vmrkloktvz)
-
01 Sep 2023
(TransCon PTH 18 mcg)
dhaqssuuaj(oszajsyvru) = owodshevme zbzclgcpcm (kcunwjkgsz, qxyizvbnqv - zhwootjxyy)
Phase 2
-
57
jmyhojnoxi(nwmukijobu) = zpnwwbvdcn dlwrderuwy (tfkzemofud )
Positive
12 Sep 2022
Phase 3
82
(exuvukanhn) = jdzzfsutcl kcerpqwify (nvjyxecxcd, 66.3 - 88.1)
Positive
13 Mar 2022
Placebo
(exuvukanhn) = wzzrrvfdge kcerpqwify (nvjyxecxcd, 0.1 - 23.8)
Phase 2
59
fannyiauen(fiiqczwksp) = lwnwxihumn cuwimxnpys (mgkamaapgn )
Positive
04 Aug 2021
-
Not Applicable
-
-
ftocuccfyp(oegacsoyij) = ewdaqbvwnx nnsdemdbyq (sydfqeldyq )
-
30 Oct 2012
FK
ftocuccfyp(oegacsoyij) = grmbsijpip nnsdemdbyq (sydfqeldyq )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free